Congress and the Trump administration have indicated that they will continue to seek new legislative measures to control drug costs, such as several recently announced “most favored nation” (“MFN”) pricing programs.
Congress and the Trump administration have indicated that they will continue to seek new legislative measures to control drug costs, such as several recently announced “most favored nation” (“MFN”) pricing programs.